From 2003 to 2013, the national prevalence of prescription opioid use disorders and associated mortality increased. Medicaid populations may be especially vulnerable to morbidity and mortality from opioid-related disorders. Limited data exist on characteristics and underlying treatment patterns for Medicaid sub-populations.

**Objectives/Specific Aims**

To describe the demographics, medical utilization, opioid utilization, and clinical characteristics of members in a state Medicaid program who used opioids or were diagnosed with opioid-related disorders during the study period.

**Methods**

State Medicaid pharmacy and medical claims data spanning January 2011 to June 2016 were analyzed. A descriptive cross-sectional design was used. Three overlapping cohorts were identified from 2012 to 2016:

1. Members with at least one claim for an opioid prescription (OP)
2. Members who had at least one ICD (965.0x, T40.x) diagnosis code for opioid overdose (OD)
3. Members who had at least one ICD (304.0x, 305.5x, F11.x) code for opioid abuse or dependence (AD)

Members were required to have at least 12 months of continuous eligibility prior to their index date (date of last opioid claim or date of last medical claim with opioid-related diagnosis)

All descriptive measures were examined in the year prior to index date

The general state Medicaid population was abstracted from eligibility files and was defined as those members who had any eligibility during 2012 to 2016

**Results**

**Prevalence of OD was highest in one of the metropolitan regions (84.1/100,000 members) and Northeast (90.0/100,000 members) regions**

**Prevalence of OD was highest in the Northeast (618.3/100,000 members) and the central metropolitan (639.1/100,000 members) region**

**References**

3. Fernandes JC, Campana D, Harwell TS, Helgerson SD. High mortality rate of unintentional poisoning due to prescription opioids in adults enrolled in Medicaid compared to those not enrolled in Medicaid in Montana. Drug Alcohol Depend. 2015;153:346-349.

**Disclosure Statement**

This study was supported by Purdue Pharma L.P.